In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jessica Merrill

New York, NY
Jessica Merrill is a Bureau Editor for US Commercial Content for Informa’s pharmaceutical news publications, including “The Pink Sheet” and SCRIP. She has been covering the pharmaceutical industry as a journalist for more than 10 years, spanning the spectrum from R&D to regulatory to commercial. She was previously a reporter and editor for “The Pink Sheet” and “Pink Sheet” DAILY, specializing in business and commercial news, focusing largely on big pharma, M&A and business development, and the commercial landscape, including drug launches and market access. Before embarking on a career in healthcare journalism, she covered business news for the cosmetics industry and worked as a newspaper reporter.

Latest From Jessica Merrill

COVID-19 Silver Lining: Top Tech Talent Takes A Closer Look At Pharma

A survey of 2,500 technology professionals across five countries conducted by Novartis finds technology talent wants to work in health care and pharma more now than before the pandemic.

Business Strategies Digital Health

Novartis Settles Foreign Bribery Charges With US Government

The company agreed to pay $233.9m to the US Department of Justice and $112m to the Securities and Exchange Commission to settle foreign bribery charges tied to South Korea, Vietnam and Greece.

Legal Issues Commercial

Gene Therapies Will Be A Bigger Cost Issue In 2021, PwC Predicts

The expected launch of BioMarin's Roctavian for hemophilia A is expected to heighten the profile of expensive gene therapies on payers' radar. Specialty drug costs are expected to continue to grow in 2021. 

Gene Therapy Rare Diseases

Pfizer’s Bourla On COVID-19 Vaccine: "There Is No ROI That Will Drive Our Decision"

CEO Bourla said he has put a disproportionate weight on helping to solve the global health crisis over general drug development during a virtual event hosted by Harvard Business Review.

Coronavirus COVID-19 Innovation

Mylan Triumphs In Tecfidera Patent Challenge

Following a district court decision invalidating the '514 patent for Tecfidera, Mylan says it looks forward to launching a generic after final FDA approval is granted, despite Biogen saying it will appeal the ruling. The ANDA has a November action date.

Intellectual Property Legal Issues

Biogen's Tecfidera Future Uncertain After Patent Challenge Loss To Mylan

Biogen said it will appeal the district court decision invalidating the '514 patent for Tecfidera but Mylan said it looks forward to launching a generic after final FDA approval is granted. The ANDA has a November action date.  

Generic Drugs Intellectual Property
See All
UsernamePublicRestriction

Register